This study is a retrospective real-world study. In this study, we plan to collect the clinical data of lung metastatic nasopharyngeal carcinoma patients who received PD-1 inhibitors and chemotherapy combined with or without radiotherapy.
age of at least 18 years;
Karnofsky Performance Status (KPS) ≥60;
histologically confirmed nasopharyngeal squamous carcinoma;
metastatic disease after primary standard treatment (patients who had metastatic diseases over six months after treatment);
previous treatment with an immune checkpoint inhibitor;
recurrent disease;
previous systemic chemotherapy for metastatic disease;
symptomatic central nervous system metastases;